Menu

Recent Interviews

Nick Mather, CEO, SolGold PLC

Nick Mather
CEO | SolGold PLC
1 King Street, EC2V 8AU London (GB)

emichael@solgold.com.au

+44 20 3823 2125

SolGold CEO Nick Mather on building a major gold and copper mining company


Jared Scharf, CEO, Desert Gold Ventures Inc.

Jared Scharf
CEO | Desert Gold Ventures Inc.
4770 72nd St,, V4K 3N3 Delta (CAN)

jared.scharf@desertgold.ca

Desert Gold Ventures CEO Jared Scharf on West Africa and its potential


Stephan Dorfmeister, Finance Department, Deep Nature Project GmbH

Stephan Dorfmeister
Finance Department | Deep Nature Project GmbH
Untere Hauptstraße 168, 7122 Gols (AT)

office@deep-nature.at

+43 681 10139055

Like Aurora Cannabis and Canopy Growth, Deep Nature Project GmbH focuses on value chain


21. January 2020 | 13:48 CET

Aphria, Cronos Group, EXMceuticals - it is a buyers' market!

  • Cannabis

The shares of numerous well-known and unknown cannabis companies have had a dramatic year 2019. Price losses of over 50% are not uncommon. What costs only half today may have become twice as attractive. Due to the large number of cannabis companies listed on the stock exchange, this is the time for investors who are planning a new investment.

time to read: 1 minutes by Mario Hose


 

Emergence of a market

Among the well-known companies in the cannabis industry are Aphria, Aurora Cannabis, Canopy Growth and also Cronos Group. In the past year new names also came onto the market, but in connection with the price losses of the big players they received little attention or suffered collateral damage.

So it may be more worthwhile than ever to put newcomers like EXMceuticals on the watch list. The cannabis market is in the development phase and in the course of this, changes in legislation around the globe as well as in the product range will be visible.

Education and pioneering work

The large companies such as Aphria and Cronos Group have done a lot of pioneering work in their home country Canada and in many other regions around the globe in recent years. Although the cannabis plant is an ancient remedy, the worldwide wave of legalization has made extensive educational work necessary for politicians, medicine and potential customers.

The confidence in new therapies does not come overnight and it requires a lot of understanding and patience to build a market for a new product universe.

EXMceuticals is building a team of experts

Compared to Aphria and Cronos Group, EXMceuticals is still in a development phase. CEO Jonathan Summers has announced numerous new additions to the team in recent months to develop the operational business with experts who have both experience and an established network.

Although EXMceuticals is headquartered in Canada, due to a shell acquisition, the operational business is located in Europe and Africa.

Entry level at low

Aphria is valued at CAD 1.8 billion market capitalization at a stock market price of CAD 7.02. The shares of Cronos Group changed hands most recently at CAD 11.27 and are valued at CAD 3.9 billion. EXMceuticals is still a lightweight with a market capitalization of 16.5 million CAD at a price of 0.45 CAD, but there is still the opportunity to enter at a low valuation level in order to profit from further developments. As is well known, the profit lies in purchasing.


Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

15. July 2020 | 12:23 CET

BioNTech, EXMceuticals, XPhyto - Covid-19 and legalizations offer potential

  • Cannabis

In recent months, the society around the globe has been going through a process of change of deceleration and standstill. Priorities have been redefined and implemented at record speeds in many places. Covid-19 serves as a catalyst for change for many people. The reasons can be different. The development of corona vaccines and antibody tests will make a lot of money in the future and the legalization of cannabis in the USA on a federal level has the potential to create a renaissance.

Read

19. May 2020 | 15:02 CET

Aphria, Aurora Cannabis, Canopy Growth, EXMceuticals - do not miss the entry!

  • Cannabis

The nationwide and anonymous advertising format of Deutsche Post is called POSTAKTUELL and is published regularly in large print runs. The stack of advertising is wrapped in a foil and the practical added value for the recipient is the TV guide. The front of POSTAKTUELL is particularly eye-catching and anyone who advertises there will reach a lot of people. In the meantime, advertising for products and applications with active ingredients from the cannabis plant is already being done there. CBD reaches the general public and despite the Corona Pandemic, the industry's stocks are running in turnaround mode and have left the lows.

Read

23. March 2020 | 15:00 CET

Aurora Cannabis, Bayer, EXMceuticals - ready for the time after Corona

  • Cannabis

The cannabis hype was over and then came the corona crisis. Investors who believed in the active ingredient of cannabis and put money into the shares of companies in this industry are now likely to be sitting on a huge loss in most cases. It all started with the idea of a few companies to make one of the oldest medicinal plants in the world acceptable for general use within the framework of legalization. However, high margins and a large market soon led to competition and a brokerage industry was earning a lot of money - soon several hundred cannabis companies were listed on the stock exchange.

Read